Clinical Trials

Esophageal Squamous Cell Carcinoma, Pathologic Complete Response, Esophageal Neoplasms, Recurrence

NCT04278274 2022-10-26

MR-AI-pCR

205 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT05534841 2022-09-10

Assessment of Complete Response MRI Criterion After Neoadjuvant Therapy in Locally Advanced Rectal Cancer

99 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT04939103 2022-09-01

TRUS-FNA For The Prediction Of pCR After Neoadjuvant Treatment In Rectal Cancer

63 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT04917263 2021-06-08

IMMUNOREACT2

544 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT04271657 2021-05-06

RPAI-pCR

100 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT03474341 2020-11-16

PRIDE

200 enrolled

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Pathologic Complete Response, Esophageal Neoplasms

NCT03426397 2020-07-29

"Wait-and-see" Policy for Complete Responders After Chemoradiotherapy for Rectal Cancer

Recruiting

220 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT04273477 2020-02-18

MRAI-pCR

100 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT03601689 2018-07-26

Predictive Factors of Disease-free Survival After Complete Pathological Response to Neoadjuvant Radiotherapy in Rectal Adenocarcinoma

84 enrolled